JPMorgan Chase & Co. Has $109.92 Million Stake in ICU Medical, Inc. (NASDAQ:ICUI)

JPMorgan Chase & Co. raised its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 7.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 708,382 shares of the medical instruments supplier's stock after purchasing an additional 49,108 shares during the quarter. JPMorgan Chase & Co. owned approximately 2.89% of ICU Medical worth $109,920,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Barclays PLC grew its holdings in ICU Medical by 15.6% in the 3rd quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier's stock valued at $10,790,000 after buying an additional 8,010 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of ICU Medical by 24.6% in the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier's stock valued at $23,130,000 after acquiring an additional 25,031 shares during the period. MetLife Investment Management LLC grew its stake in shares of ICU Medical by 129.1% in the third quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier's stock valued at $2,258,000 after acquiring an additional 6,981 shares in the last quarter. Vanguard Group Inc. boosted its holdings in ICU Medical by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 2,682,065 shares of the medical instruments supplier's stock valued at $416,176,000 after purchasing an additional 17,805 shares during the period. Finally, Jennison Associates LLC bought a new position in ICU Medical during the 4th quarter worth $556,000. 96.10% of the stock is owned by institutional investors.

Remove Ads

ICU Medical Price Performance

Shares of ICUI stock traded up $2.93 on Monday, reaching $142.25. The company had a trading volume of 437,024 shares, compared to its average volume of 266,368. The stock has a market capitalization of $3.49 billion, a PE ratio of -31.13 and a beta of 0.86. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. The business's 50-day moving average is $151.03 and its 200 day moving average is $162.18. ICU Medical, Inc. has a one year low of $93.36 and a one year high of $196.26.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. StockNews.com upgraded shares of ICU Medical from a "hold" rating to a "buy" rating in a research note on Friday. Raymond James set a $97.00 price objective on shares of ICU Medical in a research report on Wednesday, March 12th. Finally, Jefferies Financial Group raised ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 target price on the stock in a report on Wednesday, December 11th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, ICU Medical has an average rating of "Buy" and an average price target of $168.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.